Now that 2017 is in the books, let’s take a look at the past year’s cancer breakthroughs and headlines according to Memorial Sloan Kettering, one of the nation’s premier cancer centers:
The Food and Drug Administration’s approval of chimeric antigen receptor (CAR) T cell therapy for certain types of leukemia and lymphoma was the development that most shaped cancer care in 2017, most experts agree. CAR, a form of immunotherapy, uses genetically engineered versions of a patient’s own immune cells to identify and treat cancer.
Click here to read about exciting new developments in cancer care.
The Hartford HealthCare Cancer Institute is the charter member of the MSK Cancer Alliance, which is developing strategies to improve outcomes, and expedite availability of the most advanced treatments to patients no matter where they enter the Hartford HealthCare system.
The Cancer Institute’s alliance with Memorial Sloan Kettering is a partnership between national cancer experts and the oncology providers in our community. Patients benefit from the very latest cancer research knowledge and treatment regimens, conveniently in their own community setting.